<DOC>
	<DOCNO>NCT00688623</DOCNO>
	<brief_summary>To evaluate preliminary efficacy safety RAD001 monotherapy first-line treatment patient metastatic papillary carcinoma kidney .</brief_summary>
	<brief_title>RAMSETE : RAD001 Advanced Metastatic Silent Neuro-endocrine Tumors Europe</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . ≥ 18 year old 2 . Patients advance ( unresectable metastatic ) biopsy proven nonsyndromic neuroendocrine carcinoma , low intermediate grade 3 . Radiological documentation disease progression within 12 month prior study entry . If patient receive antitumor therapy past 12 month , must radiological documentation PD receive therapy 4 . Patients may receive previous treatment ( chemotherapy , biotherapy , peptidereceptor radionuclide therapy ) ; overall maximum 3 systemic treatment allow 5 . Patients least one measurable lesion 6 . Patients ECOG Performance Status 02 7 . Adequate bone marrow function 8 . Adequate liver function 9 . Adequate renal function 10 . Adequate lipid profile Exclusion criterion : 1 . Patients poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid small cell carcinoma 2 . Patients carcinoid hormone relate symptom ( diarrhea ≥ 4 stool per day and/or flush ) 3 . Patients Islet cell carcinomas pancreatic NET 4 . Patients receive prior therapy VEGF pathway inhibitor within 4 week prior study entry 5 . Patients enter PRRT within 3 month prior study entry 6 . Patients receive CT , biotherapy radiotherapy within 4 week prior study entry 7 . Patients previously receive systemic mTOR inhibitor 8 . Patients know hypersensitivity everolimus rapamycins excipients 9 . Patients uncontrolled central nervous system ( CNS ) metastases 10 . Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent 11 . Patients known history HIV seropositivity 12 . Patients autoimmune hepatitis 13 . Patients active , bleed diathesis 14 . Patients severe and/or uncontrolled medical condition condition could affect participation study 15 . Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer carcinoma situ uterine cervix 16 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control methods 17 . Patients use investigational agent receive investigational drug ≤ 4 week prior study treatment start 18 . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>non-functioning neuroendocrine tumor carcinoid</keyword>
	<keyword>non-functioning carcinoid</keyword>
	<keyword>adult</keyword>
	<keyword>everolimus</keyword>
</DOC>